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A  Randomised,  Placebo-controlled  Trial  of  the  Effects  of 
Preoperative  Pregabalin  on  Pain  Intensity  and  Opioid 
Consumption  following  Lumbar  Discectomy
Department of Anaesthesia, Intensive Care & Pain Medicine, Cork University Hospital, Wilton, Cork, Ireland
Dominic  A.  Hegarty,  MD,  and  George  D.  Shorten,  MD
Background: 
Pregabalin has been shown to have analgesic effect in acute pain models. The primary objective was to 
examine the efficacy a single dose of pregabalin, would have on morphine consumption following lumbar 
discectomy. 
Methods: 
With ethical approval a randomized, placebo-controlled prospective trial was undertaken in 32 patients (ASA 
I-II, 18-65 years) with radicular low back pain for ＞ 3 months undergoing elective lumbar discectomy. Patients 
received either oral pregabalin 300 mg (PG Group) or placebo (C Group) one hour before surgery. Pain intensity, 
the accumulative morphine consumption and adverse effects were recorded for 24 hours following surgery. 
Functional, psychological and quantitative sensory testing were also assessed.
Results: 
Fourteen patients out of the 32 recruited were randomized to receive pregabalin. Morphine consumption 
was reduced (absolute difference of 42.3%) between groups with medium effect size. (Mann-Whitney; U = 
52.5, z-score= 2.84, P = 0.004, r = 0.14). This was not associated with a significant difference in the incidence 
of adverse effects between the two groups. The median pain intensity (VAS) on movement was not significantly 
different between groups. 
Conclusions: 
A single pre-operative dose of pregabalin (300 mg) did not result in a reduction in pain intensity compared 
to placebo in this patient cohort but the significant reduction in morphine consumption suggests that a fixed 
peri-operative dosing regime warrants investigation. (Korean  J  Pain  2011;  24:  22-30)
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INTRODUCTION
    Despite major improvements in our understanding of 
acute pain physiology over the past decade, approximately 
80% of patients undergoing surgical procedures experience 
postoperative pain [1]. Acute postoperative pain is recog-
nized as a predictor of persistent post surgical pain and 
between 5 and 50% of patients reported persistent post 
surgical pain after a variety of common procedures [2]. 
Recent advances in the pathophysiology of pain have sug-
gested that it is possible to prevent or attenuate the cen-
tral neural hyperexcitability that contributes to enhanced 
postoperative pain [3]. Although opioids are an important 
component of postoperative pain management, they are 
associated with side effects, and so, a multimodal an-
algesic approach has been recommended for the manage-
ment of acute postoperative pain [4].
    Pregabalin has been shown to have a analgesic and 
o p i o i d - s p a r i n g  e f f e c t  i n  t h e  p o s t o p e r a t i v e  p e r i o d  [ 5 , 6 ] .  
However  the  analgesic  efficacy  of  pregabalin  (300  mg) 
given  pre-operatively  in  a  cohort  of  patients  known  to 
suffer from chronic pain is unknown. 
    The pre-study hypothesis is that a single pre-oper-
ative dose of pregabalin (300 mg) would result in a sig-
nificant reduction in morphine consumption with a parallel 
reduction  in  acute  pain  intensity  following  lumbar 
discectomy.
MATERIALS  AND  METHODS
1. Patient population
    With institutional ethical committee approv al and hav-
ing obtained informed written consent a prospective study 
of all ASA I-II patients, 18-65 years old, undergoing elec-
tive lumbar discectomy at a single institute were included. 
Patients were considered for inclusion if they had an inter-
vertebral disc herniation confirmed on magnetic resonance 
imaging, and persistent symptoms despite non-operative 
treatment for at least 12 weeks. Specific inclusion criteria 
were the presence of radicular pain and/ or low back pain 
and  evidence  of  nerve-root  irritation  with  a  positive 
nerve-root tension sign (straight leg raise positive between 
30
o and 70
o or positive femoral tension sign) or a corre-
sponding  neurological  deficit  (dermatomal  distribution  of 
pain, asymmetrical depressed reflex, decreased sensation 
in a dermatomal distribution, or weakness in a myotomal 
distribution). Lumbar disc protrusion was confirmed using 
pre-operative magnetic resonance imaging as reported by 
independent  radiologists.  Patients  requiring  lumbar  dis-
cectomy from L1/L2 to L5/S1 were eligible for inclusion in-
cluded provided that only one of the herniations was judged 
to be symptomatic. 
    Exclusion criteria included previous spinal surgery, 
cauda equina syndrome, known spinal or genetic abnor-
malities, pregnancy, other chronic pain states, vertebral 
fractures, spinal infection or tumour, inflammatory spon-
dyloarthropathy,  pre-operative  analgesia  management 
that included gabapentin, pregabalin or opioids in the two 
weeks prior to surgery. The use of paracetamol (1 gram), 
every 6 hours, was permitted.
2. Intervention and blinding
    Patients were randomly allocated, using a computer 
generated random numbers table, into one of two groups 
to receive (i) pregabalin 300 mg orally (PG) or (ii) a placebo 
(C) one hour before surgery. Placebo drugs consisted of 
matching sugar capsules and were prepared by the hospi-
tal pharmacy. Study medications, contained in sealed en-
velopes, were labelled with the name of the project and 
t h e  a l l o c a t ed  r a n d o m  n um b e r.  T e l e p h o n e c o m m u n i c a t i o n 
between the operating theatre and the hospital ward, en-
sured that the prescribed “pre-medication” was adminis-
trated on time. At no point was the patient, the inves-
tigators, or the healthcare staff aware of the group as-
signment until the study concluded.
3. Anaesthetic technique, analgesia & surgery
    With standard hemodynamic monitors in place and af-
ter three minutes of pre-oxygenation anaesthesia was in-
duced with fentanyl 1-2 ug/kg, propofol 2-4 ug/kg followed 
by vecuronium 0.8 ug/kg to facilitate intubation and con-
trolled ventilation. Anaesthesia was maintained using sev-
oflurane (0.8-1.5%) in N20/O2 (70：30) and intermittent ve-
curonium as clinically indicated. During surgery each pa-
tient received a fentanyl intravenous bolus of 25 ug as re-
quired if the heart rate increased by 10% compared to the 
pre-induction baseline. Each patient received paracetamol 
(1 gram) and diclofenac (75 mg) intravenously before sur-
gery commenced. Prior to skin closure the subcutaneous 
tissue was infiltrated with 10 mls of bupivacaine 2.5 mg/ml 
by the neurosurgeons. Ondansetron (4 mg, intravenously) 
was administrated for prophylaxis of nausea and vomiting 24 Korean J Pain Vol. 24, No. 1, 2011
in all cases.
    A standardised open microscopic lumbar discectomy 
surgical technique, with examination of the affected nerve 
r o o t  w a s  p e rf o r m ed  b y o n e  o f  t h r ee  c o ns u l t a n t  n e u r o-
s u r g e o n s  a t  o u r  i n s t i t u t e .  T h e  s u r g i c a l  a n d  a n a e s t h e t i c 
time (from induction to tracheal extubation) was recorded 
on the theatre computerised records.
    Each patient was prescribed paracetamol (1 g, orally) 
every six hours for 24 hours and a patient controlled an-
algesia  (PCA)  as  part  of  their  post-operative  pain 
management. This consisted of intravenous morphine (2 
mg per bolus), with a six minute lock-out interval, without 
a  c o n t i n u o u s  i n f u s i o n .  T h i s  w a s  c o m m e n c e d  i n  t h e  
post-operative care unit (PACU) and it was available to the 
patient for 24 hours post discharge from the PACU. If an-
algesia  was  inadequate,  a  nurse  practitioner  could 
over-ride the PCA protocol and administer additional in-
travenous morphine in increments of 1 mg in keeping with 
hospital policy. The total volume of morphine consumed 
was electronically recorded on the patient controlled an-
a l g e s i c  d e v i c e  f o r  t h e  d u r a t i o n  o f  t h e  s t u d y .  A d d i t i o n a l  
doses  of  ondansetron,  4  mg  intravenously,  were  ad-
ministered as clinically indicated. Patients were discharged 
to the ward from the postoperative care unit, after ap-
proximately 20 minutes and only if they had a verbal ana-
logue pain score ＜ 2 out of ten and a sedation score of 
1 out of five [7] in keeping with local protocol.
4. Clinical outcomes
    Pain intensity was recorded using a visual analogue 
scale (VAS), consisting of a 10 cm horizontal line with the 
two end-points labelled “no pain” and “worst pain ever” 
at six assessment time points: pre-operatively, on dis-
charged from the PACU, 4, 8, 12 and 24 hours following 
surgery. The VAS scores and the incidence of adverse ef-
f e c t s  w e r e  i n d e p e n d e n t l y  r e c o r d e d  b y  a  m e m b e r  o f  t h e 
acute pain team in keeping with hospital protocol for the 
use of PCA morphine. Morphine consumption was elec-
tronically recorded on the PCA device and downloaded after 
24 hours. The incidence of adverse effects; nausea, som-
nolence,  light-headedness,  headache,  dizziness,  visual 
disturbances, and vomiting were recorded at the end of the 
24 hour period and patients were asked to rate on a four 
point verbal scale (none, mild, moderate, severe) the pres-
ence and severity of each side effect if appropriate. A re-
cord of the number of patients who experienced nausea 
and/or vomiting, and the total quality of ondansteron ad-
ministrated was kept.
    The Short-form McGill pain questionnaire [8] was 
u s e d  t o  a s s e s s  p a i n  q u a l i t y  a n d  t h e  R o l a n d - M o r r i s  
Questionnaire was completed by patients to assess phys-
ical disability due to low back pain [9]. Psychological as-
s e s s m e n t  i n c l u d e d  t h e  H o s p i t a l  a n x i e t y  a n d  d e p r e s s i o n  
scale questionnaire [10,11] and pain coping strategies were 
in v estigated by the P ain Catastrophizing Scale [12]. The 
assessments were distributed to the patients for self com-
pletion at their bedside the day before surgery. The re-
searcher  explained  the  instructions  for  each  assess-
ments/questionnaires in turn and remained available to the 
patient until they were completed. Each patient received 
the assessments in the same order. A second assessment 
was completed by the patients 24 hours after surgery. On 
both  occasions  the  assessments/questionnaires  were 
checked for completeness while the patient was present. 
Following  completion  of  the  assessments/questionnaires 
the data was subsequently transferred to an electronic re-
cord (Microsoft Excel 2007) for analysis. 
5. Neurophysiological assessments
    Quantitative sensory testing was preformed pre-op-
eratively and post-operatively by a single trained inve-
stigator. The pain perception threshold to transcutaneous 
constant  current  electrical  stimulation  was  assessed  in 
each patient lying supine in a warm quiet environment us-
ing a Dantec Keypoint Neurodiagnostic stimulator. Patients 
were unable to see the monitor, were not distracted during 
the testing and were given the identical instruction. Pain 
perception thresholds were recorded, five minutes apart 
u s i n g  a  0 . 1  m A / s e c  r a m p i n g  r a t e ,  a n d  a  s t a n d a r d i z e d  
technique in the forearm (C8-T1 dermatome) contralateral 
to the nerve root involved, and in the affected dermatome 
o f  t h e  a f f e c t e d  a n d  c o n t r a l a t e r a l  l o w e r  l i m b s .  I f  t w o  
thresholds values differed by ＞ 20% between runs, testing 
was repeated until three consecutive thresholds were re-
corded each within 20% of both. 
6. Data and power analysis
    Based on previous preliminary results from our de-
partment,  the  anticipated  morphine  requirement  in  the 
f i r s t  2 4  h o u r s  f o l l o w i n g  l u m b a r  d i s c e c t o m y  w a s  1 2  m g 
(Standard deviation = 5 mg). We considered a 40% reduc-
tion in morphine consumption to be clinically relevant then, DA Hegarty and GD Shorten / Pregabalin and Post-operative Pain 25
Fig. 1. Flow diagram of patient distribution.
Table 1. The Demographic, Psychological, Functional, Pain Perception Thresholds and Analgesic Requirements for the Placebo (C) and 
Pregabalin (PG) Groups 
C group
(n = 18)
PG group
(n = 14)
P
Demographic details
  Age (yr)
  M/F
  Dermatome affected*
Duration of anaesthesia (minutes)
Duration of surgery (minutes)
Time to PACU discharge (minutes)
Psychological & Functional assessment
  PCS
†
  HADS
  RMF score
McGill pain questionnaire
Pain perception threshold (mA)
Additional analgesia consumed 
  Intra-operative fentanyl (ug) 
  Diclofenac post-operative consumption (mg)
L4
L5
S1
Total PCS
Helplessness
Rumification
Magnification
Anxiety
Depression
Pre-operative
Post-operative
41.8 ± 8.1
10/8
3
6
4
86.9 ± 15.8
60.2 ± 12.5
27.5 ± 6.5
30.5 ± 17.1
13.8 ± 8.4
5.6 ± 4.3
11.5 ± 5.0
6.7 ± 4.0
7.7 ± 4.5
16.7 ± 5.9
17.2 ± 11.2
20.8 ± 8.5
27.5 ± 15.5
122.2 ± 39.2
212.5 ± 13.3
38.8 ± 7.9
7/7
3
6
10
82.6 ± 14.8
55.5 ± 12.2
22.4 ± 3.15
35.8 ± 18.2
16.7 ± 10.3
6.7 ± 3.6
12.2 ± 8.5
7.1 ± 3.5
7.5 ± 2.3
16.2 ± 3.5
18.6 ± 8.6
25.4 ± 14.2
30.1 ± 17.4
128.5 ± 42.0
221.4 ± 24.6
NS
NS
NS
NS
NS
NS
NS
 0.003
NS
NS
NS
NS
NS
NS
NS
0.7
0.16
0.56
0.6
0.2
Data are expressed as number of cases or mean ± SD. Un-paired, Student t-tests, ANOVA(
†) and Fisher’s exact test(*) were preformed
where appropriate. NS: no significant difference between groups, PACU: post anaesthesia care unit, PCS: pain catastrophizing scale, HADS:
hospital anxiety and depression score, RMF: Roland-Morris functional score.
with an alpha = 0.05 and beta = 0.20, at least 18 patients 
are required to be enrolled in each group to allow for loss 
to follow up.
    The method of analysed was decided prospectively and 
included  unpaired  Student  t-tests,  ANOVA  and  Fisher 
Exact tests with bonferroni correction where appropriate. 
The VAS pain scores were analysed using Krushal-Wallis 
and Mann-Whitney U-tests; the incidences of side-effects 
were analysed with Fisher’s exact test. The Microsoft Excel 
(2007) package was used for statistical analysis. P = 0.05 26 Korean J Pain Vol. 24, No. 1, 2011
Table 3. Pre- and Post-operative Median Pain Intensity Scores 
Pain intensity C group PG group P value (2-tailed) CI 95%
Pre-operative VAS 
Post-operative VAS
7.1 (2-10)
1.5 (0-7)
 5.2 (1.4-10)
1.0 (0-3)
0.34
0.32
−0.9 (−2.9-0.3)
0.5 (−1.0-2.0)
Data are expressed as median with range. VAS: visual analogue score, C: placebo treated control group, PG: Pregabalin treated group.
Fig. 2. This figure represents accumulative 24 hour 
morphine consumption (mg) in the 24 hours following 
lumbar discectomy. C group: the placebo, PG group: 
pregabalin group. Boxes show interquartile ranges and the
bars are the 10
th and 90
th percentiles. Mann-Whitney 
analysis shows a significant difference in median morphine 
consumption between the C group and the PG group with
medium effect size (r) (U = 52.5, z-score = 2.84, P = 
0.004, r = 0.14).
Table 2. Pain Intensity (VAS) on Movement Pre- and Postoperatively following Lumbar Discectomy
Median pain intensity (VAS) on movement
Pre-op 4 hrs 8 hrs 12 hrs 24 hrs Kruskal-Wallis test (H)
C group (n = 18)
PG group (n = 14)
Absolute difference
 (Between the groups)
4.9
6.7
0.3
2
2
0
6
2
 0.7
3
1
 0.7
2
1
 0.5
H(5) = 52.9, P  ＜ 0.001
H(4) = 35.8, P  ＜ 0.001
C: placebo treated control group, PG: pregabalin treated group.
was considered significant. Data was presented in keeping 
with CONSORT 2010 guidelines regarding randomised trials 
(www.consort-statement.org).
RESULTS
    Thirty-six consecutive patients who fulfilled the in-
clusion criteria were considered for the study. Following 
randomization  two  patients  were  subsequently  excluded 
because  they  received  opioid  analgesia  before  surgery. 
Another two patients chose not to continue and were with 
drawn before they received their assigned “pre-medication”. 
Of the resulting thirty-two patients, 14 were randomly as-
signed to the PG group and 18 to the C group (Fig. 1). The 
baseline demographic and clinical characteristics of each 
group are shown in Table 1. Both groups were homoge-
neous  in  terms  of  pre-operative  pain  intensity,  para-
cetamol consumption, duration of pain, psychological and 
functional  scores  and  pre-operative  neurophysiological 
assessments (Table 1).
    The accumulative morphine consumption in the post- 
operative 24 hours was 2.5 times greater in the C group 
c o m p a r e d  t o  t h e  P G  g r o u p  ( 1 8 7  m g  v  7 4  m g ) .  M a n n - 
Whitney analysis shows a significant difference in median 
morphine consumption between the C group and the PG 
group with medium effect size. (U = 52.5, z-score = 2.84, 
P = 0.004, r = 0.14) (Fig. 2). This represents an absolute 
difference of 42.3% in morphine consumption during the 
study.
    The median pain intensity (V AS) on movement was 
significantly reduced following surgery in both the C group 
[Kruskal-Wallis test; H(5) = 52.9, P ＜ 0.001] and in the 
PG group [H(4) = 35.8, P = 0.001] (Table 2). No significant 
difference in pain intensity between the groups was found 
pre- or post-operatively (T able 3). Fig. 3 shows the box 
plot for the median pain scores (25
th-75
th percentiles) in 
the 24 hours following surgery. The absolute difference in DA Hegarty and GD Shorten / Pregabalin and Post-operative Pain 27
Table 4. Adverse Effects in the First 24 Hours following Lumbar 
Discectomy
Side effects
C group
(n = 18)
PG group
(n =14)
Nausea
Somnolence
Lightheadedness
Dizziness
Headache
Visual disturbances
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
16
 2
 0
 0
11
 3
 4
 0
 9
 5
 4
 0
13
 3
 2
 0
13
 4
 1
 0
16
 1
 1
 0
11
 1
 2
 0
 6
 4
 4
 0
 7
 5
 2
 0
13
 2
 3
 0
 7
 5
 2
 0
11
 2
 1
 0
Data are expressed as number of cases. C: placebo treated control
group, PG: Pregabalin treated group.
Fig. 3. Peri-operative pain intensity score (VAS) on 
movement are showing. Boxes show interquartile ranges 
and the bars are the 10
th and 90
th percentiles. Krushall- 
Wallis testing showed a significant reduction in pain scores
within both the PGB group (H(4) = 35.8, P = 0.001) and 
the placebo group (H(4) = 52.9, P  ＜ 0.001). Post hoc 
Mann-Whitney analysis showed no significant difference 
between tow groups.
VAS scores over the 24 hour study period is shown in Table 
2.
    Post hoc analysis, using Mann Whitney tests and ap-
plying a bonferroni correction so all events were reported 
at a 0.0167 level of significance, showed that both the C 
group (Mann-Whitney U-test; U = 17.5, z-score = 4.64, 
P ＜ 0.001, r = 0.7) and PG group (U = 14.0, P ＜ 0.001) 
r e p o r t e d  s i g n i f i c a n t l y  l e s s  p a i n  u p  t o  4  h o u r s  f o l l o w i n g 
surgery. Both groups continued to show a reduction in the 
median pain scores 8 and 12 hours following surgery.
    There was no diff erence in the diclof enac, paracetamol 
and fentanyl consumption in either group during the 24 
hour  peri-operative period  (Table  1).  The  most  common 
side effect was somnolence, which was typically described 
as mild to moderate by 7 patients in C group (38.8%) and 
8 patients in PG group (57%). Light headedness and dizzi-
ness were reported in our study but both were described 
as mild to moderate. No reduction in the incidence of ad-
verse effects was identified in the study (Table 4). Post-hoc 
analysis showed that when patients who did not report any 
adverse effects (absent) were compared to those who de-
s c r i b e d  t h e  s a m e  s y m p t o m  a s  m i l d / m o d e r a t e  o r  s e v e r e 
(present)  there  was  no  significant  difference  in  the  in-
cidence  of  any  of  the  adverse  effects  between  either 
groups (Table 5). Ondansetron (4 mg, intravenously), was 
administrated to two patients in both groups within the 
first 4 hours post-operative. The time to discharge from 
the post anaesthesia care unit (PACU) was slightly longer 
in the C group compared to the PG group (27.5 + 6.5 mi-
nutes vs 22.4 + 3.15 minutes, P = 0.003) (Table 1). All pa-
t i e n t s  w e r e  a m b u l a t o r y w i t h in 2 4  h o ur s  o f s ur ge ry  a n d 
w e r e  d i s c h a r g e d  f r o m  t h e  h o s p i t a l  w i t h i n  4 8  h o u r s  o f  
admission.
DISCUSSION
    The key findings of this study are firstly, there was 
a 43.2% reduction in the total opioid consumption in the 
early post operative period; however, the opioid sparing 
effect was not associated with a significant difference in 28 Korean J Pain Vol. 24, No. 1, 2011
Table 5. Correlation Analysis Between Groups for the Incidence of Post-operative Adverse Effects following Lumbar Discectomy
Adverse effects
C Group
(n = 18)
PG Group
(n = 14)
Pearson’s
X
2 P 1/odds ratio SE
Nausea
Somnolence
Lightheadedness
Dizziness
Headache
Visual disturbances
Absent
Present
Absent
Present
Absent
Present
Absent
Present
Absent
Present
Absent
Present
16
 2
11
 7
 9
 9
13
 5
13
 5
16
 2
11
 3
 6
 8
 7
 7
 9
 5
 7
 7
11
 3
0.63
1
0
0.2
0.65
0.8
0.42
0.3
0.7
0.6
0.2
0.38
0.46
0.5
1.0
0.69
0.38
0.46
0.4
1.5
0.7
0.3
0.3
0.4
The adverse-effects were classified into one of two groups; either as absent (none) or present mild/moderate/severe in Table 4. C: placebo
treated control group, PG: pregabalin treated group. X
2: pearson’s chi square test.
the incidence of adverse effects between the two groups. 
Secondly, a single dose of pregabalin (300 mg) adminis-
trated pre-operatively does not offer any significant re-
duction in pain intensity following lumbar discectomy com-
pared to placebo.
    Pregabalin has been shown to reduce acute post op-
erative pain intensity and analgesic requirements in pa-
tients undergoing elective surgery with no pre-operative 
pain profile [5,6,13]. The cohort population in our study are 
known to suffer chronic pain and the expectation is that 
central sensitisation has been established. The proposed 
m e c h a n i s m  o f  a c t i o n  o f  p r e g a b a l i n  i s  t o  l i m i t  t h e  
short-duration wind-up component of central sensitization 
by binds to the pre-synaptic alpha-2-delta subunit of the 
voltage-gated  calcium  channels  (α2δ-VGCC)  which  are 
widely distributed in the spinal cord and the brain [14,15]. 
The conformational changes induced by this binding inhibit 
abnormally intense neuronal activity by reducing the syn-
aptic release of glutamate and other neurotransmitters. 
Experimental studies with animal models and healthy hu-
man volunteers have shown that pregabalin reduces noci-
ceptive responses, particularly in conditions involving cen-
tra l sensitization [15]. Our r esults suggest that a single 
dose of pregabalin does not inhibit neuronal activity suffi-
ciently to reduce pain intensity. While we accept that a re-
duction in pain intensity would have been more clinically 
meaningful the ability of one administration of pregabalin 
to reduce morphine consumption by 43% warrants further 
investigation. 
    T o interpret our results we ha v e to consider that either 
the dose of pregabalin and the dosing regime used was in-
adequate or a combination of both. W e chose to use a 
pre-operative pregabalin dose of 300 mg because (i) this 
dose  demonstrated  a  significant  analgesic  effect  in  an 
acute pain model with an acceptable adverse profile [5,16]; 
and (ii) a peak plasma concentration can be reliably ach-
ieved with 300 mg of pregabalin within one hour due to 
the predictable and linear pharmacokinetic profile of pre-
gabalin [3,17]. As all patients in our study received their 
pre-operative intervention at the appropriate time it is ex-
pected that the peak plasma concentration for pregabalin 
was  achieved.  Other  studies  have  prescribed  pregabalin 
peri-operatively [18] but not at the dose we used; the use 
o f  f i x e d  o r  f l e x i b l e  p r e g a b a l i n  d o s i n g  r e g i m e s  w a r r a n t s 
further investigation to assess the best clinical outcome.
    Whether the use of an enriched enrolment study de-
sign would enhance the average benefit of the study drug 
over placebo and result in important differences in this co-
hort is presently unknown [19].
    W e accept that as all patients were assessed for side 
effects in the 24 hours following a general anaesthesia it 
is possible that this may have masked any side effects due 
to the pregabalin treatment. Furthermore our study was 
not powered to investigate the side-effects of pregabalin 
per se and further study design should include this fact. 
We also recognise that we failed to observe any reduction DA Hegarty and GD Shorten / Pregabalin and Post-operative Pain 29
in the incidence of side effects associated with morphine 
consumption and thereby limits the clinical impact of this 
study. This may have been related to; (i) the low morphine 
requirement post operatively; (ii) the use of a PCA delivery 
system which is designed to avoid such complications; and 
(iii) the study was not powered to identify opioid related 
adverse effects. Indeed, for these reasons using adverse 
effect as the basis for our power analysis in our clinical 
setting would have not been practical. However, the pat-
tern and degree of adverse effects we report are similar 
to those reported in previous studies [6]. No patient in our 
study withdrew due to adverse effects and no significant 
differences in adverse effects were observed between the 
placebo and pregabalin groups. The most commonly re-
ported adverse effect associated with the use of pregabalin 
is sedation [6]; we found no significant difference between 
the groups in this regard. Likewise the patient’s ability to 
ambulate postoperatively or the duration of hospital stay 
was not significantly different. 
    The study design ensured that both groups were ho-
mogenous in all other aspects and it is reasonable to con-
clude that the reduction in morphine consumption was re-
lated to the administration of pregabalin.
    In conclusion, compared to placebo, a single pre-op-
erative dose of pregabalin (300 mg) did not result in a sig-
nificant reduction in acute pain intensity following lumbar 
discectomy but the morphine consumption was reduced in 
the  24  hour  post-operative  period  following  lumbar 
discectomy. This morphine-sparing effect was not, how-
ever,  associated  with  a  reduced  incidence  of  reported 
opioid induced side-effects. Further studies are required to 
examine the benefit of continued prescribing of pregabalin 
peri-operatively following lumbar discectomy and the im-
pact that this might have on chronic post-surgical pain. 
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